HDAC6 interacts with tau and modulates its phosphorylation, and genetic deletion or pharmacological blockade of HDAC6 decreases Aβ and tau pathology and consequently improving cognitive performance in AD animal models [30, 31]. This evidence concerns the gene MAPT and Alzheimer disease.